|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002351,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205081,
umls-concept:C0205082,
umls-concept:C0205191,
umls-concept:C0376495,
umls-concept:C0406317,
umls-concept:C0679254,
umls-concept:C1122087,
umls-concept:C2825032
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1365-2133
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
164
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
434-41
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21083543-Adult,
pubmed-meshheading:21083543-Antibodies, Monoclonal,
pubmed-meshheading:21083543-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21083543-Chronic Disease,
pubmed-meshheading:21083543-Dermatologic Agents,
pubmed-meshheading:21083543-Female,
pubmed-meshheading:21083543-Humans,
pubmed-meshheading:21083543-Male,
pubmed-meshheading:21083543-Middle Aged,
pubmed-meshheading:21083543-Psoriasis,
pubmed-meshheading:21083543-Recurrence,
pubmed-meshheading:21083543-Retreatment,
pubmed-meshheading:21083543-Severity of Illness Index,
pubmed-meshheading:21083543-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
|
|
pubmed:affiliation |
Probity Medical Research, Waterloo, ON, Canada. kapapp@probitymedical.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
